ANGPT2 and colonic neoplasm: Coincidentally, the combination of ANGPT2 and VEGFA inhibition and PD-1 blockade was shown to improve tumor control, supporting the rationale for co-targeting angiogenesis and immune checkpoints for colon cancer therapy (54).